|
|
|
|
|
by rolph
2308 days ago
|
|
this is something of a bush to beat around. - when the virus docks with the ACE2 receptor there is a loss of the ACE2 receptor function as it is a destructive process. - when the virus inhabits the cell there is probably a cytoplasmic down regulation of ACE2 expression as the cell is now "claimed" as a place for replication so the question would be when would we administer or withdraw such an ACE2 blocker the loss of ACE2 functionality is devastating to the cell
but the presence of functional ACE2 receptor makes a cell vulnerable to entry -and should we be using a blocker pe se or should we use some sort of hypothetical receptor inhibitor that is not displace by coronavirus spike protien, as in competetive inhibition? |
|
Best guess? ACE2 loss is probably bad, having more ACE2 probably doesn’t drive disease severity:
https://twitter.com/__philipn__/status/1229568317167243264?s...
Relative ace2 reduction correlates w disease severity; viral load growth the same between groups - check out study!
Chinese paper discusses this as well:
https://pubmed.ncbi.nlm.nih.gov/32061198-inhibitors-of-ras-m...
They reason that 1) ARB doesn’t increase ACE2 past normal human baseline anyway, just to normal status 2) Younger have higher ACE2, older women more than older men; both groups more protected so disease severity unlikely from higher ACE2.
ACE2-fc being developed- will both stop AT1R activation and neutralize virus:
https://twitter.com/robertlkruse/status/1233986542097567744?...
He is looking for funding if any funders are reading this. Comment here and I can connect.